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Abstract: 
 
Importance: Stimulant use disorder is common, affecting between 0.3 to 1.1% of the 
population, and costs over $85 billion per year globally. There are currently no licensed 
treatments. Several lines of evidence implicate the dopamine system in the pathophysiology of 
substance use disorder. Thus understanding the nature of dopamine dysfunction seen in 
stimulant users has the potential to aid the development of new therapeutics.  
Objective: To comprehensively review the in-vivo imaging evidence for dopaminergic 
alterations in stimulant (cocaine or amphetamine/methamphetamine) drug abuse or 
dependence.  
Data sources: The entire PubMed, EMBASE and PsycINFO databases were searched for 
studies from inception date to May 14, 2016.  
Study selection: A total of 31 studies were identified that compared dopaminergic measures 
between 519 stimulant users and 512 controls using positron emission tomography or 
single-photon emission computed tomography to measure striatal dopamine synthesis or 
release, or dopamine transporter or receptor availability. 
Data extraction and synthesis: Demographic, clinical and imaging measures were extracted 
from each study and meta-analyses and sensitivity analyses were conducted for stimulants 
combined and cocaine and amphetamines separately where there were sufficient studies.  
Main Outcomes and Measures: We determined the difference in dopamine release 
(assessed using change in the D2/3 receptor availability following administration of 
amphetamine or methylphenidate), transporter and receptor availability in cocaine, 
amphetamine and methamphetamine users and healthy controls.  
Results: In majority of the studies the duration of abstinence varied from 5 days to 3 weeks. 
There was a significant decrease in striatal dopamine release (stimulants combined: Hedge͛s 
g= −Ϭ.84; cocaine: −Ϭ.87, both p<0.001), dopamine transporter availability (stimulants 
combined: Hedge͛s g= −0.91, p<0.01; amphetamine and methamphetamine: Hedge͛s g: 
−1.47, p<0.001) and D2/3 availability (stimulants combined: Hedge͛s g= −Ϭ.ϳϲ; cocaine: 
−0.73; amphetamine and methamphetamine: −Ϭ.81, all p<0.001). We did not find consistent 
alterations in vesicular monoamine transporter, dopamine synthesis or D1 receptor studies.  
Conclusion and relevance: Our data suggest that both pre and post-synaptic aspects of the 
dopamine system in the striatum are down-regulated in stimulant users. We discuss the 
commonality and difference between these findings and the discrepancies with the 
preclinical literature as well as their implications for future drug development.  
 
 
 
 
  
 
 
 
 
 
 
 
Introduction:  
According to World Health Organization estimates amphetamine-like stimulants 
(predominantly methamphetamine and amphetamine) and cocaine are the second and 
fourth most common forms of illicit substance abuse respectively (world drug report 2015; 
https://www.unodc.org). The world-wide prevalence of amphetamine-like stimulant use 
was estimated at between 0.3-1.1 percent in 2015 (between 13.8 million and 53.8 million 
users), and for cocaine it was 0.3-0.4 percent of the population aged 15-64 (between 13 
million and 20 million users) (world drug report 2015; https://www.unodc.org). Stimulant 
use is thus a significant burden to society 1. Dopamine dysregulation is hypothesized to 
underlie addictive behaviour 2-6 and stimulants such as amphetamine and cocaine act on 
dopamine transporters and increase extracellular dopamine 7-10. Furthermore, preclinical 
models show that the acute rewarding effects of stimulant drugs are linked to the release of 
dopamine in the nucleus accumbens measured using micro-dialysis or fast scan cyclic 
voltammetry 6,11. Positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) enable us to measure dopaminergic function in-vivo in 
humans 12. Using these imaging tools, human studies have found that stimulant drugs 
increase synaptic dopamine levels in the whole striatum (including ventral striatum which 
includes the nucleus accumbens) and that increases are associated with the subjective 
perception of drug reward in non-drug abusing controls 13,14.  However, determining the 
dopaminergic effects of stimulants in human stimulant users is essential as the 
neurobiological mechanisms may be different. A number of studies have investigated 
dopamine release, dopamine transporter and dopamine receptor levels in stimulant 
addiction. However, to our knowledge, there has not been a previous meta-analysis of these 
findings. Thus we aimed to synthesize the PET and SPECT imaging findings on dopaminergic 
function in cocaine and amphetamine-like (amphetamine and methamphetamine) stimulant 
addiction and to consider their implications for its treatment. Since both drugs are known to 
increase extracellular dopamine levels, either by blocking (cocaine) or reversing 
(amphetamine/methamphetamine) the dopamine transporter, we pooled the data 10. We 
group findings into studies of dopamine release, dopamine transporter availability, and 
dopamine receptor availability. We focus on the whole striatum as it is richly innervated 
with dopaminergic neurons and reliably imaged with PET and SPECT in humans 15.  
Methods:  
Study selection 
To be included in the meta-analysis, an article needed to investigate the striatal 
dopaminergic system in cocaine or amphetamine-like stimulant users (this included 
amphetamine and methamphetamine) and a control group, including the mean and 
standard deviations for both groups (see supplementary figures 1 and 2 for the study 
selection and supplementary methods for further details on the search and inclusion 
criteria). We focused on amphetamine and methamphetamine as these are the most widely 
used amphetamine-like drugs. 
Data extraction 
The main outcome measure was the difference in the dopaminergic imaging index between 
stimulant users and controls. The following variables were extracted from all the studies: 
authors, year of publication, subject characteristics of the control and stimulant users group 
(group size, age, sex, substance use characteristics, comorbid substance abuse, method of 
abstinence confirmation, duration of abstinence, diagnosis), imaging characteristics 
(method, radiotracer, scanner type and resolution), route of administration of drug 
challenge and modelling method. 
Data analysis 
The main outcome measure was the effect size for the dopaminergic index for the whole 
striatum in the stimulant users (cocaine and amphetamine-like stimulants studies 
combined) using a random effects model. Separate secondary meta-analyses were 
conducted for the studies of dopamine transporter (DAT), dopamine release and dopamine 
receptor availability in cocaine and amphetamine-like substance users to determine if the 
effects were consistent across categories of stimulants. Publication bias was assessed using 
funnel plots as well as regression tests. Heterogeneity was estimated using the I2 value (I2 
values <50% indicate low to moderate heterogeneity, whereas I2 >50% indicate moderate to 
high heterogeneity). Leave-one-out sensitivity analyses were conducted. A significance level 
of p<0.05 (2-tailed) was taken as significant (see supplementary materials for further 
methodological details).  
 
Results 
Dopamine release 
There were 7 studies (5 in cocaine users and 2 in amphetamine-like stimulant users) 
assessing dopamine release in 164 stimulant users with 139 healthy controls 16-22. The meta-
analysis showed a significant reduction in dopamine release in the stimulant users relative 
to controls with an effect size of −0.84 ([95% confidence interval (CI), −ϭ.08 - −Ϭ.ϲ0], p 
<0.001). This was also seen when the meta-analysis was restricted to cocaine users, effect 
size −0.87 ([95% CI, −ϭ.ϭϱ - −Ϭ.ϲ0], p<0.001). There were too few studies of amphetamine-
like stimulant users for a meta-analysis, but the effect sizes in the two studies were in the 
same direction (standardized mean difference (SMD): −1.05 [95% CI, −1.76 - −0.34] and 
−0.40 [95% CI, −1.11 - 0.32]) 20,21. The results of heterogeneity and sensitivity analysis are 
provided in supplementary material. 
Dopamine transporter:  
There were 12 studies (3 in cocaine users24-26 and 9 in amphetamine-like stimulant users27-
35) assessing dopamine transporter availability in 177 stimulant users and 191 healthy 
controls. The meta-analysis showed a significant reduction in dopamine transporter 
availability in the stimulant users relative to controls with an effect size of −0.91 ([95% CI, 
−1.5 - −Ϭ.ϯϮ], p<0.01). For sub-analysis, there were 9 studies in amphetamine-like stimulant 
users 27-35 assessing dopamine transporter availability in 108 stimulant users and 126 
healthy controls. The meta-analysis showed significantly reduced dopamine transporter 
availability in amphetamine-like stimulant users (effect size: −1.47 ([95% CI, −ϭ.ϴ3 - −ϭ.ϭ], 
p<0.001). There were 5 studies in cocaine users 24-26,36,37. However, one study was excluded 
as it included cocaine users with potential CNS co-morbidity (HIV) 36.  This left too few 
studies for a separate meta-analysis in cocaine users. The results of these studies were 
inconsistent, with the two PET studies (where there was an overlap of samples) showing no 
significant difference in the DAT availability in cocaine users 26,37, whilst the two SPECT 
studies reported elevated DAT in cocaine users who were acutely abstinent 
24,25
. The two 
SPECT studies in cocaine users had durations of abstinence of a maximum of 4 days25  and mean of 7 
days. 24 As such, residual cocaine could block radiotracer binding to DAT, resulting in a slight 
underestimation of DAT levels in these studies. The results of heterogeneity and sensitivity 
analysis are provided in supplementary material. 
Dopamine receptor availability 
There were 19 studies assessing dopamine receptor availability in 342 stimulant users and 
321 healthy controls (7 studies in amphetamine-like stimulant users 20,21,38-42 and 12 studies 
in cocaine users 16-19,22,37,43-48).  
The meta-analysis revealed an overall reduction in D2/3 receptor availability in stimulant 
users relative to controls with an effect size of −Ϭ.ϳϲ ([ϵϱ% CI, −Ϭ.ϵ2 - −Ϭ.ϲ], p<0.001). In the 
separate analyses a reduction in D2/3 receptor availability was noted in both cocaine users 
(effect size=−Ϭ.ϳϯ [ϵϱ% CI, −Ϭ.ϵϰ - −Ϭ.ϱϯ], p<0.001) and amphetamine-like stimulant users 
(effect size=−0.81 [ϵϱ% CI, −ϭ.12 - −Ϭ.ϰϵ], p<0.001) relative to controls. The results of 
heterogeneity and sensitivity analysis are provided in supplementary material. 
 
Other dopaminergic measures: 
There was only one study in stimulant users using ϲ‐[ϭϴF]fluoro‐dihǇdroǆǇ‐pheŶǇlalaŶiŶe 
;[ϭϴF]‐DOPAͿ assessing dopamine synthesis capacity 49. This study showed reduced 
dopamine synthesis capacity in cocaine users and the estimated effect size was found to be 
0.46 [95% CI, −0.46 - 1.39]. We could not find any studies on dopamine synthesis capacity in 
amphetamine-like stimulant users. Four studies assessed vesicular monoamine transporter -
2 (VMAT2) availability, with inconsistent findings. Two studies showed significantly reduced 
VMAT2 availability, one in cocaine users with two weeks of abstinence [Hedge͛s g: 1.6, 95% 
CI: 0.68 - 2.52] 50, and the other in methamphetamine abusers after three months of 
aďstiŶeŶĐe [Hedge͛s g: ϭ.ϲϴ, 95% CI: 0.86 - 2.5] 28. However, two studies in recently 
abstinent methamphetamine users (mean duration of abstinence: 2.6 days and 19 days) 
shoǁed eleǀated VMATϮ leǀels [Hedge͛s g: ϭ.ϭϲ, ϵϱ% CI: Ϭ.ϱϲ - 1.76] 51,52. Moreover, given 
that metamphetamine interacts with VMAT2 at the same site as the PET tracers and the 
relatively short duration of abstinence, it is possible that VMAT2 levels were 
underestimated in some subjects.    
There was only one study on stimulant users and D1 receptors, which used [11C] NNC112 to 
compare cocaine abusers with controls 53.  Though there were no differences in D1 
receptors between groups, the availability of D1 receptors in cocaine abusers was negatively 
associated with the choice to self-administer cocaine by the cocaine abusers 
Discussion: 
To our knowledge this is first meta-analysis investigating the nature of dopaminergic 
dysfunction in stimulant users. Our main findings are that dopamine release, transporter 
levels and D2/3 receptor availability are all lower in vivo in stimulant users compared to 
healthǇ ĐoŶtrols ǁith large to ǀerǇ large effeĐt sizes ;Hedge͛s g: −Ϭ.ϴϰ, −Ϭ.ϵϭ aŶd −Ϭ.ϳϲ 
respectively). This indicates that there is a generalised down-regulation of the dopaminergic 
system in stimulant users, as summarised in Figure 4. Our sensitivity analyses of the 
dopamine D2/3 receptor availability and dopamine release findings showed consistent 
results and we noted low heterogeneity across studies of cocaine and amphetamine-like 
drugs, and across differing radiotracers and techniques. However, there was a difference 
between results in amphetamine/methamphetamine and cocaine drug users in dopamine 
transporter availability. In amphetamine/methamphetamine users there were large and 
consistent reductions in dopamine transporter availability.  In contrast for cocaine users, 
despite the limited number of studies preventing sub-analysis, there were two studies that showed 
no difference 26,54 and two other studies that reported elevated dopamine transporter availability, 
both in acutely abstinent cocaine users 24,25. This may point to a mechanistic difference between the 
effects of amphetamine-like drugs and cocaine on dopamine transporters, consistent with preclinical 
findings55, and highlights the need for more studies in cocaine users. Cocaine is known to primarily 
act by blocking DAT, while amphetamine competitively inhibits dopamine re-uptake at DAT, and 
increases DAT mediated reverse-transport of dopamine from the cytoplasm into the synaptic cleft 
independent of action potential evoked vesicular release.7-9 It has also been suggested that 
aŵphetaŵiŶe͛s aĐtioŶs depeŶd oŶ its ĐoŶĐeŶtratioŶ, ǁith it aĐtiŶg priŵarilǇ as a DAT ďloĐker at loǁ 
concentrations and reversing dopamine transport at high concentrations.7 In addition, 
amphetamine-like stimulants are known to trigger internalization of plasmalemmal DAT.56 Finally, 
cocaine, amphetamine and methamphetamine are also known to act on serotonin and 
norepinephrine transporters, although their affinities for these are different. 57 Given these 
pharmacological differences between stimulants, there could be differences in dopaminergic effects 
between stimulants that are masked by pooling studies. 
There are some specific issues that affect interpretation of the results. For studies of D2/3 receptors, 
the tracers generally used do not distinguish between D2 and D3 receptors, or between the high and 
low affinity forms of the D2 receptor, so the reduction could reflect a change in one, or more of 
these. However, two studies used [11C]-PHNO, which is selective for the D2 high affinity form and 
shows a higher affinity for D3 receptors over D2 receptors. These studies did not show significant 
differences between stimulant users and controls in the striatum 44,46. This could suggest that the 
reduction seen in our meta-analysis reflects a reduction in the low affinity form of the D2 receptor 
availability.  Also, given that the radiotracers used to measure D2/3 receptor availability are sensitive 
to endogenous dopamine levels 58, one possible interpretation of our finding of reduced D2/3 
receptor levels is that this reflects elevated synaptic dopamine levels. However, a dopamine 
depletion study in cocaine users has shown that baseline synaptic levels are also reduced43. This 
indicates that the reduction in D2/3 receptor availability represents a reduction in D2/3 receptor 
levels. Furthermore, when our findings are taken with the observation of reductions in synaptic 
dopamine levels 43, and dopamine synthesis capacity 49, they suggest there is a generalised reduction 
in presynaptic dopaminergic activity. Although, with the available data we could not specifically rule 
out the possibility of upregulation D3 receptor. 
Limitations 
In common with other meta-analyses of psychiatric imaging studies 59-63, there are variations 
between studies in terms of both the sample characteristics, such as the inclusion of current or 
abstinent users, co-morbid use of other substances such as nicotine and alcohol and variations in the 
durations of abstinence, and methods, in particular in the radiotracer used and delineation of the 
striatum (see supplementary discussion).  
Nevertheless, there was low heterogeneity across the analyses, with the exception of the dopamine 
transporter, and the random effects model we used allows for variations in effects.  Furthermore, if 
anything, these variations between studies would obscure rather than account for the effects we 
observed. A general limitation of the literature, apparent in the funnel plots, is that there are few 
studies with large sample sizes. It should also be noted that there have been a relatively small 
number of studies on dopamine release and we could not investigate potential differences between 
oral and intravenous routes of drug challenge to elicit dopamine release. Although, in absolute 
terms the oral challenge studies showed lower release than those using an intravenous route, both 
indicated blunted release in stimulant users compared to controls. 
Implications for understanding stimulant misuse and dependence 
Preclinical studies using in vivo micro-dialysis and chronoamperometry conclusively demonstrate 
that acute administration of stimulants increases extra-cellular dopamine concentrations in the 
striatum, and nucleus accumbens. 11 Furthermore, in vivo fast-scan cyclic voltammetry and 
implantable micro-sensor studies, which are able to quantify the dopamine signalling over a sub-
second timescale, have shown that stimulants increase phasic dopamine release 6,11, and human in 
vivo imaging studies also show evidence consistent with acute exposure of stimulants leading to 
increased synaptic dopamine either through cue induced dopamine release or blockade of DAT, and 
that this is liŶked to suďjeĐtiǀe ͚high͛ 54 and craving66,67. Moreover, change in in vivo dopamine 
imaging indices, following amphetamine administration, has been shown to be directly related to 
change in microdialysis measures 68, providing convergence across methods. Thus there is 
consistency between the preclinical and clinical findings indicating that acute administration of 
stimulants results in increased extra-cellular dopamine either by stimulating release (amphetamines) 
or by DAT blockade (cocaine). 
Our meta-analysis shows a consistent reduction in dopamine release in people who have been 
exposed to chronic stimulants. In contrast, preclinical models of chronic use are inconsistent, with 
some studies showing no change in basal dopamine output after withdrawal of chronic 
amphetamine 69-72 and cocaine 73-77, whilst others have reported increases in dopamine output after 
cocaine withdrawal 78-81. The first major implication of our meta-analysis is thus that the findings in 
many preclinical models of chronic use do not reflect what is seen in the human studies. This 
suggests caution in extrapolating from preclinical models, and may explain the failure to develop 
treatments for stimulant addiction based on them. There are a number of potential explanations for 
this inconsistency, including differences in the dosing regimens and durations used in preclinical 
models relative to human usage patterns. Nevertheless, this discrepancy suggests we need to 
develop new preclinical models that reproduce the dopaminergic changes seen in the human 
condition.   
Our findings are also striking in showing reductions in both presynaptic and post-synaptic aspects of 
the dopaminergic system, suggesting a generalised down-regulation. One potential explanation for 
the reduction in dopamine release and transporter availability (seen in 
amphetamine/methamphetamine  users only) could be a loss of dopamine neurons per se or 
damage to the dopaminergic terminals.  There is evidence that both cocaine and amphetamines 
induce apoptosis as indexed by activation of caspases, loss of mitochondrial potential, cytochrome c 
release and oxidative stress. 82 However, in addition to this, amphetamine and methamphetamine 
induce dopaminergic neuron damage through the formation of quinones and free radicals. 83-85 
Moreover, preclinical models with methamphetamine have shown evidence of dopamine terminal 
damage that recovers with detoxification 86,87.  Furthermore, in humans, dopamine transporters 
recover with detoxification in methamphetamine abusers (reviewed in 5,35), which was interpreted to 
indicate that dopamine neurons were not lost.  Moreover in the only post-mortem study we could 
find, which was in methamphetamine abusers, there was evidence of reduction in dopamine 
transporters but not of dopamine neuronal loss 88.  However preliminary evidence from two recent 
epidemiological studies that methamphetamine abuse might increase the risk for ParkiŶsoŶ͛s 
disease 89,90 suggests that in some cases its abuse might accelerate age-associated dopamine 
neuronal degeneration 91 . 
It has been suggested that repeated drug use causes tolerance by various mechanisms including 
dopamine receptor alterations, changes in second messenger systems and altered regulation of 
dopamine neuron function.92-94  Thus, it is possible that the dopaminergic differences noted in our 
meta-analysis could be due to the development of tolerance through one or more of these 
mechanisms.  Pre-clinical studies have also demonstrated that dopaminergic synaptic transmission is 
modulated by glutamatergic and GABAergic neurons94. Neuroimaging studies investigating these 
interactions are needed to determine if this is the case in humans.  
Two alternative basic models are possible to account for both our pre and post-synaptic findings. 
The first is that repeated stimulant use results in adaptive changes in the dopamine system that lead 
to reduced firing of dopamine neurons, potentially similar to the depolarisation blockade that is seen 
after a period of repeated firing 95, and consequently reduced dopamine synthesis and release. In 
this context, reduced transporter levels may be compensatory in response to reduced tonic 
dopamine levels in the synapse. The reduction in D2/3 receptor levels is less easy to understand in 
the context of the presynaptic reductions. However, D2/3 receptors undergo internalisation 
following activation by dopamine, and this would reduce radiotracer binding, at least to a number of 
the tracers used in the studies in our analyses 96,97. Thus the reduction in D2/3 receptor availability 
could reflect a compensatory increase in internalized D2/3 receptors, which would reduce the 
number of D2/3 receptors available to bind to dopamine. Repeated exposure may lead to loss of 
these internalized receptors and long-term transcriptional changes that reduce receptor availability.  
The second model is that reductions underlie the pathoetiology of stimulant misuse, and precede its 
onset. Thus individuals at risk of stimulant misuse may have reductions in dopamine release, 
transporter levels and D2/3 receptor levels secondary to genetic and/or environmental risk factors. 
Reductions in D2/3 receptor levels and reduced release of dopamine to stimulants could mean an 
individual is less sensitive to the effects of taking a stimulant, leading to escalating use. However, it is 
less easy to see how reduced dopamine transporter levels fit with this model, as they would be 
anticipated to prolong the effects of stimulants.  Longitudinal studies on the effects of stimulant 
drugs on patients with attention deficit disorder showed downregulation of dopamine release with 
chronic exposure 98, which indicates that some of the changes are driven by chronic drug exposures. 
Finally, a hybrid model may best account for our findings. Evidence suggests that reduced D2/3 
receptor levels may precede and predispose to the onset of stimulant misuse but also show further 
reductions during stimulant use 99, and similar effects may be seen with dopamine release and 
transporter levels. It is interesting to note in our meta-analysis that dopaminergic alterations are 
marked even in the studies of several months abstinence, with evidence suggesting that dopamine 
receptor density and release are down-regulated even after 9 months of abstinence 35. This suggests 
that effects may persist, with implications for understanding relapse. Our findings also support the 
opponent process model 100.  
This highlights one fundamental issue raised by our meta-analysis, namely that current findings do 
not address the temporal relationship between down-regulation in the dopamine system and phase 
of addiction. Future longitudinal human PET studies as well as preclinical studies that investigate 
changes in the dopamine system prior to and during stimulant misuse-, and following abstinence are 
needed to test these models (Box 1; supplementary material). In addition this will help to identify 
biomarkers to guide treatment and predict outcomes.  
Clinical implications of our findings 
Our data identify a number of clear targets for treatment interventions. D2/3 receptors stand-out, 
given our finding of a large effect size reduction. This is further supported by studies in cocaine and 
in methamphetamine users showing that lower dopamine D2/3 receptor availability at baseline 
predicts relapse following treatment 19 21. Our data also provide a rationale for the development of 
drugs that target the presynaptic dopaminergic system to restore tonic striatal dopamine release, 
which is necessary for the function of the striato-cortical indirect pathway (a key system disrupted in 
addiction) 5. This is supported by recent preclinical evidence showing that administration of the 
dopamine precursor L-DOPA restored the aberrant dopaminergic signalling in a cocaine addiction 
animal model 6,100, and preliminary clinical evidence that inhibiting dopamine reuptake (e.g., 
with bupropion, modafinil, or mazindol), or inhibiting dopamine metabolism (e.g., with selegiline or 
disulfiram) might hold some promise in the treatment for stimulant addiction 101. Strategies to 
upregulate striatal D2 receptors have been shown in animal models to protect against compulsive 
stimulant drug intake 102 and, thus, interventions that lead to D2 up-regulation, such as physical 
activity as recently shown in a preliminary study in methamphetamine abusers 103, merit further 
investigation.  A number of dopaminergic treatments have been tried to treat stimulant use disorder 
with limited success to date.104-106  Our data suggest some potential explanations for the lack of 
success and identify a number of clear targets for treatment interventions. D2/3 receptors stand-
out, given our finding of a large effect size reduction. This is further supported by studies in cocaine 
and in methamphetamine users showing that lower dopamine D2/3 receptor availability at baseline 
predicts relapse following treatment 19 21. Our findings may also explain why strategies to block 
dopamine neurotransmission, for example using dopamine receptor antagonists107 , have largely 
been disappointing to date as dopamine receptor levels are already low, and suggest that strategies 
to increase dopamine receptor levels or sensitivity could have potential. 
Conclusions  
There is robust evidence for down-regulated presynaptic and post-synaptic dopamine function in 
stimulant addiction with large effect sizes. These findings suggest that drug development should 
target the restoration of dopaminergic function as a target for the treatment of stimulant addiction.  
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Figure 1: Studies of dopamine release in stimulant users.  
The forest plot shows the effect sizes estimated using a random effects model and 95% confidence 
intervals of the percentage change in the difference of change in D2/3 binding after challenge. There 
was an overall decrease in dopamine release in stimulant users relative to controls with a large to 
ǀerǇ large effeĐt size ;−Ϭ.ϴϰ [ϵϱ% CI, −ϭ.Ϭϴ - −Ϭ.ϲϬ], p<Ϭ.ϬϬϭͿ Schrantee et al. 2015 and Wang et al. 
2012 studied amphetamine-like stimulant users. The remaining studies included cocaine users.  
 
Figure 2: Studies of dopamine transporter availability. 
 The forest plot shows the effects sizes estimated using a random effects model and 95% confidence 
intervals of the difference between amphetamine/methamphetamine users and controls. There was 
an overall decrease in the dopamine transporter availability in methamphetamine users relative to 
ĐoŶtrols ;−Ϭ.ϵϭ [ϵϱ% CI, −ϭ.ϱ - −Ϭ.ϯϮ], p <Ϭ.ϬϭͿ 
Figure 3: Studies of dopamine receptor availability.  
The forest plot shows the effect sizes estimated using a random effects model and 95% 
confidence intervals of D2/3 receptor binding potentials. There was an overall decrease in 
dopaŵiŶe reĐeptor aǀailaďilitǇ Đoŵpared to ĐoŶtrols ;−Ϭ.ϳϲ [ϵϱ% CI, −Ϭ.ϵϮ - −0.60], 
p<0.001).  
Figure 4: A summary of dopaminergic alterations in stimulant users 
Summary of the synaptic location of the major dopaminergic findings from our meta-analyses and 
findings from studies of other aspects of the dopamine system. 
1. Based on study by Wu et al. 1997 
2. Based on study by Boileau et al. 2008 & 2015 
3. Based on study by Narendran et al. 2012 and Johanson et al. 2006 
4. Meta-aŶalǇsis fiŶdiŶg ǁith effeĐt size of −Ϭ.ϴϭ [ϵϱ% CI, −ϭ.ϯϰ - −Ϭ.Ϯϵ], p<Ϭ.Ϭϭ 
5. Meta-analysis finding with effeĐt size of −Ϭ.ϵϭ [ϵϱ% CI, −ϭ.ϱϬ - −Ϭ.ϯϮ], p<Ϭ.Ϭϭ 
6. Meta-aŶalǇsis fiŶdiŶg ǁith effeĐt size of −Ϭ.ϳϭ [ϵϱ% CI, −Ϭ.ϵϭ - −Ϭ.ϱϮ], p<Ϭ.ϬϬϭ 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary methods 
Search strategy 
The Pubmed, EMBASE and PsycINFO databases were searched from inception date to May 
14, 2016 for relevant papers without language restrictions. The electronic searches using 
EMBASE and PsycINFO were carried out together using Ovid. The following keywords were 
used for cocaine use: ͞;PositroŶ EŵissioŶ ToŵographǇ OR PET OR SiŶgle photoŶ eŵissioŶ 
tomography OR SPET OR Single Photon Emission Computed Tomography OR SPECT) AND 
(dopamine OR dopamine release OR dopamine synthesis OR dopamine availability OR 
dopamine transporter OR dopamine reuptake OR dopamine receptor) AND (cocaine OR 
ĐoĐaiŶe aďuse OR ĐoĐaiŶe depeŶdeŶĐeͿ͟. Furtherŵore the folloǁiŶg keǇǁords ǁere used 
for amphetamine-like suďstaŶĐe use: ͞;PositroŶ EŵissioŶ ToŵographǇ OR PET OR SiŶgle 
Photon Emission Tomography OR SPET OR Single Photon Emission Computed Tomography 
OR SPECT) AND (dopamine OR dopamine release OR dopamine synthesis OR dopamine 
availability OR dopamine transporter OR dopamine reuptake OR dopamine receptor) AND 
(amphetamine OR amphetamine abuse OR amphetamine dependence OR 
methamphetamine OR methamphetamine abuse OR methamphetamine dependence OR 
ŵethǇlpheŶidate OR ŵethǇlpheŶidate aďuse OR ŵethǇlpheŶidate depeŶdeŶĐeͿ͟. IŶ 
addition the reference lists in the included studies and relevant review papers were 
screened to search for additional studies.  
Inclusion and exclusion criteria 
The inclusion criteria were: 1) original molecular imaging studies that indexed dopamine 
receptors, dopamine transporters and/or dopamine release or synthesis; 2) in patients with 
a diagnosis of cocaine or amphetamine/ methamphetamine dependence or abuse and 3) 
reported data for the whole striatum or a striatal sub-region. We excluded studies which did 
not have a healthy control group or that included subjects with CNS co-morbidity. For 
studies with an overlap in participants, we included the study with the largest sample size 
without potentially missing any subjects and excluded the smaller  study from the meta-
analysis to avoid duplication of subjects.  
Outcome measures 
Our primary outcome was the effect size for the difference in the dopaminergic index for 
the whole striatum between the stimulant user and control groups. Some studies only 
reported values for striatal subdivisions. Where this was the case, we averaged the striatal 
subdivision values to estimate the value for the whole striatum as described in other 
imaging meta-analyses 1,2.  
Meta-analysis 
The statstodo software was used for the estimation of pooled standard deviation 
(http://statstodo.com/ComMeans_Pgm.php). Plot digitizer software was used to extract the 
data from studies where data was available only in a plot format 
(http://plotdigitizer.sourceforge.net/). The statistical analysis of the extracted data was 
ĐoŶduĐted usiŶg the R statistiĐal prograŵŵiŶg laŶguage ǀersioŶ ϯ.Ϯ.Ϯ ǁith the ͚ŵetafor͛ 
package. One study reported data on dopamine receptor availability with both [11C] 
raclopride and 11C-(+)-4-propyl-9-hydroxynaphthoxazine ([11C]-(+)-PHNO). We included the 
[11C] raclopride data for the main analysis to maintain consistency with the other studies, 
more of which had also used this tracer than had used [11C] PHNO. However we also 
discuss the [11C] PHNO findings where relevant. A minimum of five studies was required to 
conduct a meta-analysis as findings from meta-analyses with small numbers of studies may 
be less stable. Two independent authors (A.H.A. and Y.M.) conducted the electronic search 
and assessed studies for eligibility, while data extraction was carried out by A.H.A. and 
results of analyses confirmed by Y.M. and O.D.H. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary results: 
Dopamine release  
Heterogeneity and sensitivity analyses 
Methylphenidate challenge was used to index dopamine release in 5 studies while one 
study each used intravenous amphetamine and dexamphetamine challenge. The I2 value 
was 0 % (95% CI, 0%-70%), indicating low heterogeneity. The regression test for funnel plot 
asymmetry was not significant (t = 0.69, df = 5, p = 0.52), suggesting publication bias is 
unlikely. In addition, the trim-and-fill analysis indicated that there were no missing studies 
on the funnel plot (Supplementary figure 3).  The summary effect size reached significance 
in all cases in the leave-one-out analysis, with summary effect sizes varying from −0.78 to 
−0.90 (all p<0.001).  
Among the 7 studies investigating dopamine release, two studies used oral methylphenidate 
challenge while the others used intravenous challenge. Since only two studies used the oral 
challenge, we could not perform sub-analysis to investigate effect of route of administration. 
However, it appears that an oral challenge produces less dopamine release [ effect size: -0.43 and - 
0.57
4
]  compared to an iv challenge, although further studies are needed to directly test this. 
 Dopamine transporter  
Heterogeneity and sensitivity analyses 
The I
2
 value was 84 % (95% CI, 69%- 94%), indicating high heterogeneity between studies. 
The regression test for funnel plot asymmetry was significant (t =-2.5, df = 10, p = 0.03). In 
addition, visual inspection of the funnel plot revealed asymmetry, indicating possible 
publication bias. The trim-and-fill analysis indicate two missing studies on the right side of 
the funnel plot (Supplementary figure 4). However, the results remained significant after 
correcting for putatively missing studies [effect size= -0.68, (95%CI, - 1.3 - - 0.09), p=0.02]. 
The summary effect size reached significance in all cases in the leave-one-out analysis, with 
summary effect sizes (SMD) varying from -0.77 to -1.07 (all p<0.01).  
Dopamine receptor availability 
Heterogeneity and sensitivity analyses 
The I2 value was 0 % (95% CI, 0 %- 57 %), indicating heterogeneity was low. The regression 
test for funnel plot asymmetry was not significant (t = -1.1, df = 17, p = 0.27). However, a 
visual inspection of the funnel plot revealed asymmetry, indicating possible publication bias. 
The trim-and-fill analysis indicated that there were potentially five missing studies on the 
funnel plot (Supplementary figure 5). Nevertheless, the summary effect size remained large 
and highly significant after correcting for these putatively missing studies (corrected effect 
size: −0.66 [95% CI, −0.83 - −0.5]; z: -8; p<0.001). The summary effect size reached 
significance in all cases in the leave-one-out analysis, with summary effect sizes varying 
from SMD = −0.72 to −0.8 (all p<0.001). To investigate the effect of radiotracer on the 
outcome measure, we performed sub-analysis of studies which used [11C] raclopride. The 
results remained significant with an effect size of -0.69 [95% CI, -0.9—0.48; p<0.001].  
 
 
 
 
 
 
Supplementary discussion: 
Moreover, where a value was not given for the whole striatum, we derived this by averaging the 
data for sub-regions. These variations may add noise to the findings. Thus the effect sizes calculated 
from these studies should be considered an estimate. It should also be noted that there are 
differences in dopaminergic indices between striatal sub-regions. For example D3 receptor levels are 
higher in ventral than dorsal striatum. 5,6 Most of the radiotracers used to measure D2-like receptor 
levels have similar affinities for both D2 and D3 receptors. Thus the reduction in whole striatal D2/3 
receptor levels we report could potentially mask sub-regional increases in D3 receptors or 
differences in the ratio of D2 to D3 receptors. Unfortunately there were insufficient studies 
reporting data from sub-regions for us to investigate sub-regional dopaminergic changes and only 
two studies in cocaine users used [11C]-PHNO, a tracer that does show significant selectivity for D3 
over D2 receptors.7,8 Interestingly, in contrast to our overall findings, the two studies that used [11C] 
PHNO did not show significant differences in BPND between stimulant users and controls in the whole 
striatum. 5,6 One explanation could be that an increase in D3 in ventral striatum is off set by a 
reduction in D2 receptors in dorsal striatum. However, neither study reported a significant 
difference in ventral striatum with [11C]-PHNO. Moreover, studies which used [11C] raclopride 
demonstrated reduced ventral as well as whole striatal D2/3 availability.9-13. Taken together, these 
lines of evidence suggest our findings in the whole striatum are not explained by opposing sub-
regional differences. Nevertheless, the absence of marked differences in the [11C]-PHNO studies is 
intriguing and warrants further investigation.  
 
Supplementary figure 1. Flowchart showing the inclusion of studies for the meta-analysis 
on dopaminergic function in cocaine users 
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Records after duplicates removed  
(n=975) 
Records screened  
(n=975) 
Studies included in quantitative synthesis 
(meta-analysis) (n=15)
*1
 
Dopamine release: 5 
Records excluded  
(n=928) 
Full-text articles assessed for eligibility 
(n=47) 
Full-text articles excluded for the following 
reasons 
  Reviews, editorials, commentaries (n=12) 
  No healthy control group (n=10) 
Studies included in qualitative synthesis 
(n=19) 
Insufficient number of studies for the 
quantitative synthesis (meta-analysis) 
  Dopamine synthesis (n=1) 
  Vesicular monoamine transporter (n=1) 
  D1 receptor (n=1) 
Additionally excluded study for the 
Full-text articles remaining  
(n=19) 
Additional articles identified through hand-
search of reference lists (n=0) 

Supplementary figure 2. Flowchart showing the inclusion of studies for the meta-analysis on 
dopaminergic function in amphetamine-like stimulant users 
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 Dopamine release studies also reported on D2/3 availability. 
Studies included in quantitative synthesis 
(meta-analysis) (n=16)*
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Supplementary figure 3: Funnel plot of dopamine release studies in stimulant users 
 
 
Supplementary figure 4: Funnel plot of dopamine transporter studies in stimulant users 
◦ indicate potentially missing studies 
 
 
 
 
 
 
 
 
  
 
 
 
Supplementary figure 5: Funnel plot of dopamine D2/3 receptor studies in stimulant users 
◦ indicate potentially missing studies 
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Supplementary table 1: Molecular imaging studies on dopamine release in stimulant users compared to healthy controls  
Author/year Patients/ 
Controls, 
n 
Dopamine 
release paradigm 
Diagnosis Duration of 
abstinence  
Co-
morbid 
substance 
abuse 
Abstinence 
confirmed by 
Region of 
interest 
Tracer Reference 
region 
Measure Results in 
patients 
compared 
to 
controls 
Cocaine users 
Volkow et al. 
1997
14
 
20/23 i.v. MP challenge DSM-IV, cocaine 
dependence 
3-6 wk Nicotine 
and 
caffeine 
Toxicological 
drug screens 
before scan 
Striatum, 
thalamus 
[11C] 
raclopride 
Cerebellum Δ Bmax/ Kd ↓ 
Volkow et al. 
2014
13
 
43/19 i.v. MP challenge 
with concomitant 
cocaine cue-video  
DSM-IV, cocaine 
dependence 
Mean(SD) = 
5(5) d 
Nicotine Not specified Striatum 
prefrontal 
cortex 
[11C] 
raclopride 
Cerebellum Δ BPND ↓  
Volkow et al. 
2005
15
 
21/15 i.v. MP challenge DSM-IV, cocaine 
dependence 
Maximum 1 
mo, mean(SD) 
= 14(7) d 
Nicotine 
and 
caffeine 
Supervised 
admission 
Striatum [11C] 
raclopride 
Cerebellum Δ Bmax/ Kd ↓ 
Martinez et 
al. 2007
11
 
24/24 i.v. amphetamine 
challenge 
DSM-IV, cocaine 
dependence 
Minimum 14 d Nicotine Supervised 
admission 
Striatum [11C] 
raclopride 
Cerebellum Δ V3 ↓ 
Martinez et 
al. 2011
9
 
25/24 Oral MP 
challenge 
DSM-IV, cocaine 
dependence 
Minimum 14 d Nicotine Supervised 
admission or 
repeated urine 
drug screen 
Striatum [11C] 
raclopride 
Cerebellum  Δ BPND ↓ 
Amphetamine-like stimulant users 
Schrantee et 
al. 2015
16
 
16/19 i.v. dAMPH 
challenge  
dAMPH users 
with ≥ϯϬ lifetiŵe 
aŶd ≥ϭϬ past Ǉear 
exposures 
Minimum 1 
wk 
Nicotine Multi-drug 
screen on a 
urine sample 
before scan 
Striatum [123I] 
IBZM 
Occipital 
cortex 
BPND ratio ↓ 
Wang et al. 
2012
3
 
16/15 Oral MP 
challenge 
DSM-IV, MA 
dependence 
Minimum 2 
wk 
Nicotine Urine 
screening tests 
Striatum [11C] 
raclopride 
Cerebellum Δ BPND ↓ 
Volkow et al. 
2015
17
 
*1
 
16/15 Oral MP 
challenge 
DSM-IV, MA 
abuse or 
dependence 
Minimum 2 
wk 
Nicotine Urine 
screening tests 
Striatum [11C] 
raclopride 
Cerebellum BPND ratio ↓ 
37 
 
Abbreviations: BP, binding potential; d, days; dAMPH, dexamphetamine; i.v., intravenous; MA, methamphetamine; mo, months; MP, methylphenidate; SD, 
standard deviation; wk, weeks 
*1 Excluded from the meta-analysis on dopamine release due to overlapping participants with Wang et al. 2012. 
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Supplementary table 2: Molecular imaging studies on other presynaptic dopaminergic indices in stimulant users 
Dopaminergic 
measure 
Author/year Patients/ 
Controls, n 
Diagnosis 
 
 
Duration of 
abstinence  
 
Abstinence 
confirmed by 
Co-morbid 
substance 
abuse 
Region of 
interest 
Tracer Measure Results in 
patients 
compared 
to controls 
Cocaine users 
Dopamine 
synthesis 
capacity 
Wu et al. 1997
18
 11/8 DSM-III-R, cocaine 
dependence  
Less than 
30 d 
Frequent random 
urine drug screens 
during admission 
Not 
mentioned 
Striatum [18]-6-FDOPA Ki ↓ 
Vesicular 
Monoamine 
Transporter 2 
Narendran et al. 
2012
19
 
12/12 DSM-IV, cocaine 
dependence  
Minimum 2 
wk 
Witnessed urine 
sampling 3 times a 
week for 2 weeks in 
outpatient setting 
and 2 day 
admission 
Nicotine Striatum [11C]DTBZ BPND ↓ 
Amphetamine-like stimulant users 
Vesicular 
Monoamine 
Transporter 2 
Boileau et al. 
2008
20
 
16/14 DSM-IV, MA 
dependence or abuse 
Recently 
withdrawn, 
mean(SD) = 
19(24) d 
Urine sample for 
drug toxicology 
Nicotine Striatum [11C]DTBZ BPND ↑ 
Boileau et al. 
2015
21
 
28/22 DSM-IV, MA 
dependence or abuse 
2 scans, 
mean(SD) = 
2.6(2.0) and 
9.9(2.3) d 
Urine and blood 
samples for drug 
toxicology 
Nicotine Striatum [11C]DTBZ BPND ↑ 
Johanson et al. 
2006
22
 
16/18 DSM-IV, past MA 
dependence 
Minimum 3 
mo 
Urine drug screen Nicotine, 
past abuse 
of other 
drugs were 
allowed 
Striatum [11C]DTBZ BP ↓ 
Abbreviations: BP, binding potential; d, days; MA, methamphetamine; mo, months; SD, standard deviation; wk, weeks 
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Supplementary table 3: Molecular imaging studies on dopamine transporter availability in stimulant users compared to healthy controls 
Author/year Patients/ 
Controls, 
n 
Diagnosis Duration of 
abstinence 
Abstinence confirmed 
by 
Co-morbid 
substance 
abuse 
Region of 
interest 
Reference 
region 
Tracer Measure Results in patients 
compared to controls 
Cocaine users 
Volkow et al. 
1996
23
 
*1
 
12/20 DSM-III-R, 
cocaine 
dependence  
3-6 wk Random urine 
samples at least twice 
a week during 
admission 
Nicotine 
and caffeine  
Basal 
ganglia, 
thalamus, 
occipital 
cortex  
Cerebellum [11C]Cocai
ne 
 
Distribution 
volume ratio 
↔ 
Wang et al. 
1997
24
 
20/20 DSM-IV, 
cocaine 
dependence 
Active users, 
mean(SD) = 
5(8) d 
Pre-scan urine tests 
ensured the absence 
of psychoactive drugs 
except cocaine 
Not 
specified  
Striatum Cerebellum [11C]Cocai
ne 
 
Distribution 
volume ratio 
↔ 
Crits-Christoph 
et al. 2008
25
 
21/21 DSM-IV, 
cocaine 
dependence 
Minimum 1 d, 
mean(SD) = 
7.5(9.7) d 
History, urine drug 
screen for other 
substance use 
Nicotine 
and 
cannabis 
Striatum Elliptical ROI 
was placed on 
two 
consecutive 
slices of the 
supratentorial 
uptake 
 
99mTc 
TRODAT-1. 
Distribution 
volume ratio 
↑ 
Malison et al. 
1998
26
 
28/24 DSM-III-R, 
cocaine 
dependence 
Maximum of 
96 hours 
Urine laboratory test 
to rule out other illicit 
drug use 
Not 
specified 
Striatum Occipital cortex [123I]b-
CIT 
Distribution 
volume ratio 
↑ 
Amphetamine-like stimulant users 
Johanson et al. 
2006
22
 
16/18 DSM-IV, 
past MA 
dependence 
Minimum 3 
mo 
Urine drug screen Nicotine, 
past abuse 
of other 
drugs were 
allowed 
Striatum Occipital cortex [11C] 
Methylphe
nidate  
BP ↓ 
McCann et al. 
1998
27
 
6/10 MA users 
(diagnostic 
criteria not 
Minimum 2 
wk 
Blood and urine drug 
screens before scan 
No 
restrictions 
Striatum Cerebellum [11C]WIN-
35,428 
BP ↓ 
40 
 
specified) 
McCann et al. 
2008
28
 
7/16 DSM-IV, MA 
users 
Minimum 2 
wk 
Urine drug screen No 
restrictions 
Striatum Cerebellum [ 
11C]WIN-
35,428 
BP ↓ 
Sekine et al. 
2001
29
 
11/9 DSM-IV, MA 
users 
Minimum 7 d, 
range 7 d-1.5 
years 
Urinary drug screening 
test 
Occasional 
nicotine and 
alcohol 
Striatum, 
nucleus 
accumben
s, 
prefrontal 
cortex 
Cerebellar 
cortex 
[ 
11C]WIN-
35,428 
BP ↓ 
Volkow et al. 
2001
30
 
15/18 DSM-IV, MA 
dependence 
Minimum 2 
wk, mean(SD) 
= 5.9(9.0) mo, 
range 0.5-
36.0 mo 
Urine toxicology 
screen 
Nicotine Striatum Cerebellum [11C]d-
threo- 
methylphe
nidate 
Bmax/Kd ↓ 
Volkow et al. 
2015
17
 
16/15 DSM-IV, MA 
abuse or 
dependence 
Minimum 2 
wk, mean(SD) 
= 102(49) d 
Urine screening tests Nicotine Striatum Cerebellum [11C]cocai
ne 
BPND ↓ Đaudate, putaŵeŶ aŶd 
ventral striatum 
Chou et al. 
2007
31
 
7/7 DSM-IV, MA 
abuse  
Two scans 
(baseline and 
after 2 wk 
abstinence) 
Drug urine analysis 
used to exclude 
polysubstance abuse 
Nicotine Striatum Occipital region Tc-99m 
TRODAT 
SUR ↓ ďaseliŶe, 
partial recovery after two 
wk 
Schouw et al. 
2013
32
 
8/10 Recreational 
dAMPH 
users, more 
than 40 
occasions of 
previous use 
Minimum 2 
wk, mean(SD) 
= 1.1(1.3) mo 
Urine drug screening No caffeine 
on scan day 
Striatum Occipital cortex [123I]FP-
CIT 
Binding ratio: 
striatum to 
occipital cortex 
↓ 
 
41 
 
Yuan et al. 
2014
33
 
25/25 DSM-IV-TR, 
MA 
dependence 
Three scans 
(24-48 hours, 
2 wk, and 4 
wk abstinence 
Urine drug screen None 
 
Striatum Occipital cortex 99mTc-
TRODAT-1 
SUR ↓ 
Volkow et al. 
2001
34
 *
2
 
12/11 DSM-IV, MA 
dependence 
Mean(SD) = 
64 ± 40 d 
Urine drug screen Nicotine 
and caffeine 
Striatum Cerebellum [11C]d-
threo-
methylphe
nidate 
Bmax/Kd ↓ 
Sekine et al. 
2003
35
 *
3
 
11/9 MA users 
(diagnostic 
criteria not 
specified) 
Minimum 7 d 
abstinence 
Not specified Not 
specified 
Orbitofron
tal cortex, 
prefrontal 
cortex, 
amygdala 
Cerebellum  [11C]WIN 
35,428 
BP ↓ 
Yuan et al. 
2015
36
 *
4
 
25/21 DSM-IV, MA 
dependence 
2 wk Urine drug screen None Striatum Occipital cortex 99mTc-
TRODAT-1 
SUR ↓ 
Abbreviations: BP, binding potential; d, days; dAMPH, dexamphetamine; MA, methamphetamine; mo, months; ROI, region of interest; SD, standard deviation; SUR, specific uptake ratio; wk, weeks 
*1 Excluded from the meta-analysis on dopamine transporter availability due to overlapping participants with Wang et al 1997. 
*2 Excluded from the meta-analysis on dopamine transporter availability due to overlapping participants with Volkow et al. 2001. 
*3 Excluded from the meta-analysis on dopamine transporter availability due to overlapping participants with Sekine et al. 2001. 
*4 Excluded from the meta-analysis on dopamine transporter availability due to overlapping participants with Yuan et al. 2014. 
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Supplementary table 4: Molecular imaging studies on baseline D2/3 availability in stimulant users compared to healthy controls 
Author/year Patients/ 
Controls, 
n 
Diagnosis Duration of 
abstinence 
Abstinence confirmed by  Co-morbid 
substance 
abuse  
Region of 
interest 
Reference 
region 
Tracer Measure Results in 
patients 
compared 
to 
controls 
Cocaine users 
Martinez et al. 2011
9
 25/24 DSM-IV, cocaine 
dependence 
Minimum 14 
d 
Supervised admission or 
repeated urine drug 
screen 
Nicotine Striatum Cerebellum [11C]raclopride BPND ↓ 
Martinez et al. 2009
10
 15/15 DSM-IV, cocaine 
dependence 
Minimum 14 
d 
Admitted for 14 d and 
underwent random urine 
toxicology tests 
Nicotine  Striatum Cerebellum [11C]raclopride BPND ↓ 
Volkow et al. 1993
37
 20/20 DSM-III-R, cocaine 
dependence 
Minimum 8 
d 
Random urine samples at 
least twice a wk during 
hospitalization 
Nicotine 
and caffeine 
Striatum Cerebellum [18F]N-
methylspiroperid
ol 
Ratio 
index 
↓ 
Volkow et al. 1996
23
 12/20 DSM-III-R, cocaine 
dependence 
3-6 wk Random urine samples at 
least twice a wk during 
hospitalization 
Nicotine 
and caffeine 
Basal ganglia, 
cortex, 
thalamus  
Cerebellum  [18F]N-
methylspiroperid
ol 
Distributio
n volume 
ratio 
↓ 
Volkow et al. 1997
14
 20/23 DSM-IV, cocaine 
dependence 
3-6 wk Toxicological drug 
screens before scan 
Nicotine 
and caffeine 
Striatum, 
thalamus 
Cerebellum [11C]raclopride Bmax/ Kd ↓ 
Payer et al. 2014
6
 15/15 DSM-IV, cocaine 
dependence 
Mean (SD) 
50.1(64.4) d; 
range 7-240 
d 
Urine drug screen Nicotine, 
caffeine and 
cannabis 
Striatum 
 
Cerebellum  [11C]raclopride BPND ↓  
Volkow et al. 2014
13
 43/19 DSM-IV, cocaine 
dependence 
Mean(SD) = 
5(5) d 
Not specified  Nicotine Striatum 
 
Cerebellum [11C]raclopride BPND ↓  
Matuskey et al. 2014
5
 10/10 DSM-IV, cocaine 
dependence 
Mean(SD) = 
7(4) d 
Urine drug screen Nicotine, 
caffeine and 
cannabis 
Amygdala, 
hypothalamus
, striatum, 
thalamus 
Cerebellum [11C](+)PHNO BPND ↑ 
amygdala, 
hypothala
mus and 
substantia 
Ŷigra; ↔ 
striatum 
43 
 
Narendran et al. 2011 
12
 
10/10 DSM-IV, cocaine 
dependence 
Minimum 2 
wk 
Witnessed urine sampling 
3 times a wk for 2 wk in 
outpatient setting and 2 
d admission 
Nicotine Striatum Cerebellum [11C] raclopride BPND ↓ 
Martinez et al. 2007
11
 24/24 DSM-IV, cocaine 
dependence 
Minimum 14 
d 
Supervised admission Nicotine Striatum Cerebellum [11C] raclopride BP (ml/g) ↓ 
Volkow et al. 1990
38
 10/10 DSM-III-R, cocaine 
abuse 
Minimum 2 
d, range 2-
30 d 
Not specified Nicotine 
and caffeine 
Striatum Cerebellum [18F]N-
methylspiroperid
ol 
Ratio 
Index: 
striatum 
to 
cerebellu
m 
↓ iŶ 
detoxified 
for one wk 
or less 
↔ after 
one mo 
Volkow et al. 2005
15
 21/15 DSM-IV, cocaine 
dependence 
Maximum 1 
mo, 
mean(SD) = 
14(7) d 
Supervised admission Nicotine 
and caffeine 
Striatum Cerebellum [11C]raclopride Bmax/Kd ↓ 
Payer et al. 2014
6
 *
1
 15/15 DSM-IV, cocaine 
dependence 
Mean(SD) = 
50.1(64.4) d; 
range 7-240 
d 
Urine drug screen Nicotine, 
caffeine and 
cannabis 
Striatum 
 
Cerebellum [11C](+)PHNO 
 
BPND ↔  
 
Martinez et al. 2004
39
 
*
2
 
17/17 DSM-IV, cocaine 
abuse or 
dependence 
19-21 d Random urine testing 
during admission 
Nicotine Striatum 
 
Cerebellum [11C]raclopride BP ↓  
Wiers et al. 2016a
40
 
*3
 38/42 Cocaine abusers 
(criteria not 
specified) 
Mean(SD) = 
5(5) d (From 
Volkow et al. 
2014) 
Not specified Nicotine Striatum 
 
Cerebellum [11C]raclopride BPND ↓ 
Wiers et al. 2016b
41
 
*4
 24/21 DSM-IV, cocaine 
dependence 
Mean(SD) = 
5(5) d (From 
Volkow et al. 
2014) 
Not specified Nicotine Striatum 
 
Cerebellum [11C]raclopride BPND ↓ 
Amphetamine-like stimulant users 
Ballard et al. 2015
42
 27/27 DSM-IV, MA 
dependence 
4-7 d Supervised admission and 
urine test on scan day 
Nicotine 
and 
cannabis 
Striatum Cerebellum [18F]fallypride BPND  ↓  
 
Boileau et al. 2012
43
 16/16 DSM-IV, MA abuse Mean(SD) = Urine drug screen on Nicotine Substantia Cerebellar [ 11C]-PHNO BPND ↑ 
44 
 
or dependence 18.5(20.5) d, 
range 6-90 d 
scan day nigra, globus 
pallidus, 
ventral 
pallidum, 
striatum  
cortex Substantia 
nigra, 
globus 
pallidus, 
ventral 
pallidum 
↓ 
striatum  
Iyo et al. 1993
44
 6/10 DSM-III-R, history 
of MA abuse and 
psychotic 
symptoms 
Minimum 1 
mo, range 2 
mo-3 years 
Not specified 
 
 
Occasional 
alcohol 
Striatum, 
frontal cortex 
Cerebellum [11C]N-
Methylspiperone 
K͛ ↔ iŶ 
striatum,  
↓ 
striatum 
to frontal 
cortex 
ratio 
Volkow et al. 2001
45
 15/20 DSM-IV, MA 
dependence 
Minimum 2 
wk, range 2 
wk-35 mo 
Urine toxicology screen Nicotine Striatum  Cerebellum [11C]raclopride Bmax/Kd ↓ 
Wang et al. 2012
3
 16/15 DSM-IV, MA 
dependence 
Minimum 2 
wk 
Urine screening tests Nicotine Striatum Cerebellum [11C] Raclopride BPND ↓ 
Okita et al. 2016
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  27/20 DSM-IV, MA 
dependence 
Mean(SD) = 
6.9(2.24) d 
Urine testing Nicotine 
and 
marijuana 
Amygdala, 
striatum 
Cerebellum [18F] fallypride BPND ↔ iŶ 
amygdala, 
↓ iŶ 
striatum 
Schrantee et al. 2015
16
 16/19 dAMPH users with 
≥ϯϬ lifetiŵe aŶd 
≥ϭϬ past Ǉear 
exposures 
Minimum 1 
wk 
Nicotine Multi-drug 
screen on a 
urine 
sample 
before scan 
Striatum Occipital 
cortex 
[123I] IBZM BPND ↓ 
Lee et al. 2009
47
 
*5
 22/30 DSM-IV, current 
MA dependence 
4-10 d Residing at a research 
center during study 
Nicotine Striatum Cerebellum [18F]fallypride BPND ↓ 
Ballard et al. 2015
48
 
*6
 18/18 DSM-IV, MA 
dependence 
4-7 d Supervised admission Nicotine 
and caffeine 
Striatum Cerebellum  [18F] fallypride BPND ↓ 
Okita et al 2015
49 *7
 23/17 DSM-IV, MA 
dependence 
Mean(SD) = 
7.2(3.11) d, 
range: 4-15 
Nicotine, cannabis and 
alcohol 
Admission 
and urine 
screening 
Striatum Cerebellum [18F] Fallypride BPND ↓ 
45 
 
d 
Abbreviations: BP, binding potential; d, days; dAMPH, dexamphetamine; MA, methamphetamine; mo, months; N/A, not applicable; SD, standard deviation; SUR, specific uptake ratio; wk, weeks 
*1 [11C] PHNO data was excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with [11C] raclopride data. 
*2 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Martinez et al. 2007. 
*3 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Volkow et al. 2014. 
*4 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Volkow et al. 2014. 
*5 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Ballard et al. 2015. 
*6 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Ballard et al. 2015. 
*7 Excluded from the meta-analysis on dopamine receptor availability due to overlapping participants with Lee et al. 2009. 
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Box 1: Future research direction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preclinical research 
 Develop preclinical models that reflect the chronic usage seen in human users and measure levels of 
dopamine receptors, transporters and release prior to and following chronic use in longitudinal studies 
 Use translational methods such as imaging so findings can be directly related to human studies  
 Evaluate dosing regimens (both doses and patterns) that reflect human usage  
 Develop genetic or other models that reproduce the magnitude of lower dopamine receptor, transporter and 
release levels seen in human users and determine if these increase the risk of the animals self-administering 
stimulants  
 Determine if reduced dopamine release, transporter and receptor levels seen in chronic stimulant use are 
reversible with abstinence 
 
Clinical research 
 Determine if the reduced dopaminergic activity is a pre-existing vulnerability factor or a direct result of 
repeated drug exposure 
 Determine the dopaminergic changes over the course of stimulant use and its reversibility with abstinence.  
 Determine dopaminergic activity in extra-striatal regions in stimulant addiction.  
 Address the possible confounding factors which may affect dopamine signalling such as disrupted sleep 
patterns, obesity and co-morbid substance use (particularly of tobacco)  
 Determine the interaction of the dopaminergic system with the glutamatergic and GABAergic systems.  
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Figure 1: Studies of dopamine release in stimulant users. The forest plot shows the effect 
sizes estimated using a random effects model and 95% confidence intervals of the 
percentage change in the difference of change in D2/3 binding after challenge. There was 
an overall decrease in dopamine release in stimulant users relative to controls with a large 
to very large effect size (−Ϭ.ϴϰ [ϵϱ% CI, −ϭ.Ϭϴ - −Ϭ.ϲ0], p<0.001)  
 
Schrantee et al. 2015 and Wang et al. 2012 studied amphetamine-like stimulant users. The 
remaining studies included cocaine users.  
 
 
 
 
 
 
Figure 2: Studies of dopamine transporter availability. The forest plot shows the effects sizes 
estimated using a random effects model and 95% confidence intervals of the difference between 
amphetamine/methamphetamine users and controls. There was an overall decrease in the 
dopaŵiŶe traŶsporter availaďility iŶ ŵethaŵphetaŵiŶe users relative to ĐoŶtrols ;−Ϭ.9ϭ [95% CI, 
−ϭ.5 - −Ϭ.ϯϮ], p <Ϭ.ϬϭͿ 
 
Figure 3: Studies of dopamine receptor availability. The forest plot shows the effect sizes 
estimated using a random effects model and 95% confidence intervals of D2/3 receptor 
binding potentials. There was an overall decrease in dopamine receptor availability 
compared to controls (−0.76 [9ϱ% CI, −0.92 - −0.ϲ0], p<0.001).  
 
Figure 4: A summary of dopaminergic alterations in stimulant users 
Summary of the synaptic location of the major dopaminergic findings from our meta-
analyses and findings from studies of other aspects of the dopamine system.  
 
 
 
1. Based on study by Wu et al. 1997 
2. Based on study by Boileau et al. 2008 & 2015 
3. Based on study by Narendran et al. 2012 and Johanson et al. 2006 
4. Meta-analysis finding with effect size of −Ϭ.ϴϭ [ϵϱ% CI, −ϭ.ϯϰ - −Ϭ.Ϯϵ], p<Ϭ.Ϭϭ 
5. Meta-analysis finding with effect size of −Ϭ.ϵϭ [ϵϱ% CI, −ϭ.ϱϬ - −Ϭ.ϯϮ], p<Ϭ.Ϭϭ 
6. Meta-analysis finding with effect size of −Ϭ.ϳϭ [ϵϱ% CI, −Ϭ.ϵϭ - −Ϭ.ϱϮ], p<Ϭ.ϬϬϭ 
